Advertisement

Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px
Document › Details

Pierre Fabre S.A.. (5/4/18). "Press Release: Pierre Fabre Group – Appointment of a New Chief Executive Officer". Castres.

Organisations Organisation Pierre Fabre S.A.
  Group Pierre Fabre (Group)
  Organisation 2 Pierre Fabre Participations
  Group Pierre Fabre (Group)
Products Product pharmaceutical
  Product 2 cosmetics
Persons Person Ducournau, Eric (Pierre Fabre 201807– CEO before CEO of Pierre Fabre Dermo-Cosmetics joined 2000)
  Person 2 Parmentier, Bertrand (Pierre Fabre 201602–201806 Group CEO RETIRED 6/18)
     


Eric Ducournau has been appointed Chief Executive Officer of the Pierre Fabre Group, taking over from Bertrand Parmentier who has announced his retirement. The new CEO will assume his position on the 2nd of July, 2018, to allow for a smooth hand-over between the two men.

This appointment was decided by Pierre Fabre Participations - the Group’s holding company, chaired by Pierre-Yves Revol - which is responsible for appointing its top executives. This decision was approved by the Pierre Fabre S.A. Board of Directors at its meeting today in Castres.

In his remarks, Pierre-Yves Revol recognized “Bertrand Parmentier’s immense role in meeting the challenge of continuing the Group’s international development after the death of its Founder & Chairman, while at the same time preserving its regional identity, independence, and competitiveness.” He praised “the outstanding work ethic and commitment, the human qualities, and the unfailing loyalty of a leader who has served the Group in the noblest sense of the word for more than two decades.” “In appointing Eric Ducournau as his successor,” he added, “we are once again choosing a leader from within the Group. Eric has a firm grasp of all our areas of business and perfect knowledge of company culture, and has headed our main activity for the past six years. Moreover, he has the skills and the time needed to develop and implement the strategy that will allow continued growth in Pharmaceuticals, Consumer Health Care, and Dermo-Cosmetics over the next decade.”

Eric Ducournau, aged 50, has served as CEO of Pierre Fabre Dermo-Cosmetics since his appointment by Mr. Pierre Fabre in October 2012, prior to which, he held positions of increasing responsibility since joining the company in 2000. After heading the President Office from 2000 to 2005, he was named Group Secretary-General from 2006 to 2011, handling duties including Group legal affairs and market access for the Pharmaceuticals branch. In 2011, he was appointed Group Deputy Managing Director, assuming the additional responsibilities of heading Quality, Regulatory Affairs, and Pharmacovigilance. In the wider world of Pharmaceuticals, Eric Ducournau, representing the Group, was one of the cofounders of G5 Santé, an association of the biggest French pharmaceutical companies, and a member of the LEEM executive committee (France’s Pharmaceuticals industry association).


About Pierre Fabre:

With a portfolio representing a continuum of activities spanning from prescription drugs and consumer healthcare products to dermo-cosmetics, Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world, the 2nd largest private French pharmaceutical group and the market leader in France for products sold over the counter in pharmacies. Its portfolio includes several global brands and franchises among which Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Galénic, Elancyl, Naturactive, Pierre Fabre Health Care, Pierre Fabre Oral Care, Pierre Fabre Dermatologie and Pierre Fabre Oncologie.

In 2017, Pierre Fabre generated 2,318 million euros in revenues, of which 62% came from its international business and 61% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, counts about 13,500 employees worldwide, owns subsidiaries and offices in 47 countries and enjoys distribution agreements in over 130 countries. In 2017, Pierre Fabre dedicated ca. 175 million euros to R&D efforts, split between oncology, central nervous system, consumer healthcare, dermatology and dermocosmetics.

Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognized public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan.

The independent French certification group AFNOR audited Pierre Fabre for its corporate social responsibility policy at the “exemplary” level, according to the ISO 26000 standard for CSR.

www.pierre-fabre.com @PierreFabre


Press Contacts:

Christelle TOUCHET, Corporate Communications:
+33 (0)1 49 10 81 33 / christelle.touchet@pierre-fabre.com
Marc ALIAS, Corporate Communications Director:
+33(0)5 63 71 47 58 / marc.alias@pierre-fabre.com

   
Record changed: 2018-05-16

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Pierre Fabre (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioPharm America 2018 Boston September 600x60px




» top